Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.74), $0.07 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $49.3 million versus the consensus estimate of $45.73 million.

GUIDANCE:

Revance Therapeutics sees FY2023 revenue of $460-480 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.